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ABSTRACT
The Cobas Amplicor PCR system (CA-PCR) was
compared with culture and staining for acid-fast
bacilli (AFB) for the early detection of Mycobac-
terium tuberculosis in respiratory clinical speci-
mens and otherwise normal sterile body fluids.
The sensitivity, specificity and positive and
negative predictive values of CA-PCR were
determined with AFB-positive and AFB-negative
specimens. The sensitivity of CA-PCR ranged
from 73.6% to 100% for AFB-positive samples,
while sputa collected after bronchoscopy were
the most useful specimens, with 70% sensitivity
and 98.6% specificity among the AFB-negative
samples.
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The re-emergence of tuberculosis in combination
with the appearance of multidrug-resistant strains
has intensified the need for rapid methods to
identify mycobacteria. In western Greece, the
average annual incidence rate of tuberculosis is
5.4 ⁄ 100 000 population, with a significant under-
estimate in cases reported officially [1]. Staining
for acid-fast bacilli (AFB) to identify the Mycobac-
terium tuberculosis complex (MTB) is considered to
be a method of low sensitivity [2,3] and, although
time-consuming, the standard detection method
remains culture of specimens, with optimum
results obtained with the use of both solid and
liquid media [2,4,5].
The use of nucleic acid amplification tech-
niques provides a sensitive and specific approach
for the identification of MTB directly in clinical
specimens [3,6,7]. The Cobas Amplicor PCR
system for the detection of MTB (CA-PCR; Roche
Diagnostic Systems, Branchburg, NJ, USA) com-
bines specimen processing with automated
amplification and detection. The present study
investigated the sensitivity, specificity and posit-
ive and negative predictive values of CA-PCR in
comparison with culture results for AFB-positive
and AFB-negative respiratory specimens, as
well as for samples from normally sterile body
fluids.
In total, 3414 specimens (Table 1) from 2365
patients (1–3 specimens ⁄patient) with suspected
tuberculosis were processed during 2001–2003 by
the Microbiology Laboratory at the University
Hospital of Patras. This institution is a tertiary-
care general hospital with 750 beds, and
c. 100 000 ambulatory visits and 52 000 admis-
sions annually. All patients were admitted either
to the University Hospital or the Specialised
Hospital for Pulmonary Diseases, together ser-
ving a population of 740 000 inhabitants in
western Greece.
All specimens were processed according to
conventional procedures for identification of
mycobacteria; bronchoalveolar lavage (BAL)
specimens smaller than 20 mL were excluded
from further study [4]. Decontamination of all
specimens, except those from otherwise sterile
sites, was performed with N-acetyl-L-cysteine-
NaOH (BBL MycoPrep; Becton Dickinson, Coc-
keysville, Maryland, MD, USA). Blood-stained
specimens were also subjected to decontamina-
tion. Sediments following decontamination were
used for direct microscopy and culture, while
1-mL aliquots were stored at ) 70C until required
for DNA amplification. Smears were stained by
the Ziehl–Neelsen (Z-N) acid-fast technique and
examined by standard procedures [2]. Cultures
were performed by inoculating sediments directly
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on to Lo¨wenstein–Jensen slants (bioMe´rieux,
Lyon, France) and into Bactec Myco ⁄ F-Sputa
and Bactec Myco ⁄ F Lytic culture vials (Becton
Dickinson). Lo¨wenstein–Jensen slants were exam-
ined on a weekly basis for 40 days. Culture vials
were incubated in the Bactec 9000MB instrument
(Becton Dickinson), which is fully automated and
provides continuous monitoring [8]. If no growth
was observed following incubation for 8 weeks,
specimens were reported as culture-negative.
Mycobacterial growth was confirmed by Z-N
staining, while identification to the species level
was achieved by PCR and hybridisation with
specific DNA probes (GenoType Mycobacteria;
Symbiosis, Asti, Italy).
CA-PCR for MTB was performed according to
the manufacturer’s instructions. Samples were
washed with Tris-HCl containing solubiliser 1%
v ⁄v and the sediments were used for DNA
extraction. Specimens showing inhibition of the
CA-PCR internal control were retested after sam-
ple dilution as described previously [9]. Based on
Table 1. Comparison of the Cobas Amplicor PCR (CA-PCR) results with culture and staining results for detection of the
Mycobacterium tuberculosis complex (MTB)
Specimen
Smear result
Ziehl–Neelsen (Z-N) Number CA-PCR
Culture result
Sensitivitya
%
Specificityb
%
PPVc
%
NPVd
%Positive (324) Negative (3090)
Sputa (684)e Z-N-positive 106 Positive 67 3 73.6 80 95.7 33.3
Negative 20 10
Inhibited 4 2
Z-N-negative 578 Positive 25 9 52.1 98.3 73.5 95.8
Negative 18 498
Inhibited 5 23
BAL (1473) Z-N-positive 29 Positive 14 1 82.4 91.7 93.3 78.6
Negative 3 11
Inhibited 0 0
Z-N-negative 1444 Positive 30 19 42.9 98.6 61.2 97.1
Negative 40 1355
Inhibited 0 0
SAB (625) Z-N-positive 24 Positive 14 1 93.3 88.9 93.3 88.9
Negative 1 8
Inhibited 0 0
Z-N-negative 601 Positive 21 8 70.0 98.6 72.4 98.4
Negative 9 560
Inhibited 0 3
TA (296) Z-N-positive 17 Positive 9 0 75.0 100 100 62.5
Negative 3 4
Inhibited 0 1
Z-N-negative 279 Positive 4 4 25.0 98.5 50 95.6
Negative 12 251
Inhibited 0 8
Pleural (189) Z-N-positive 2 Positive 1 0
Negative 0 1
Inhibited 0 0
Z-N-negative 187 Positive 1 1 33.0 99.5 50 98.9
Negative 2 183
Inhibited 0 0
Gastric (23) Z-N-positive 5 Positive 4 0
Negative 1 0
Inhibited 0 0
Z-N-negative 18 Positive 2 1
Negative 2 12
Inhibited 0 1
Sterile fluids (124) Z-N-positive 1 Positive 1 0
Negative 0 0
Inhibited 0 0
Z-N-negative 123 Positive 0 0 – 100 – 91.2
Negative 11 108
Inhibited 0 4
Total (3414) Z-N-positive 184 Positive 110 5 77.5 88.1 95.7 53.6
Negative 28 34
Inhibited 4 3
Z-N-negative 3230 Positive 83 42 45.6 98.6 66.4 96.8
Negative 94 2967
Inhibited 5 39
BAL, bronchoalveolar lavage; SAB, sputa expectorated after bronchoscopy; TA, tracheal aspirate.
aAbility of PCR to detect MTB, expressed as a percentage (number of positive samples detected by CA-PCR ⁄number positive by culture).
bAbility of PCR to recognise negative MTB samples, expressed as a percentage (number of negative samples by CA-PCR ⁄number negative by culture).
cPositive predictive value, expressed as a percentage (number of positive samples by both methods ⁄number positive by CA-PCR).
dNegative predictive value, expressed as a percentage (number of negative samples by both methods ⁄number negative by CA-PCR).
eNumber of samples.
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the subsequent results, specimens were charac-
terised as either PCR-positive or PCR-negative.
Specimens were considered positive by culture
for MTB if they grew on solid or in liquid media.
Eleven AFB-positive and CA-PCR-negative spec-
imens that yielded mycobacteria other than
M. tuberculosis were excluded from the study.
Statistical analysis was conducted using the SPSS
v. 12.0 software package for Windows (SPSS Inc.,
Chicago, IL, USA).
Table 1 compares the results of Z-N staining
with CA-PCR and culture. Of the 3414 samples
tested, 184 (5.4%) were Z-N-positive, of which
110, as well as 83 of the Z-N-negative specimens,
were positive for MTB by CA-PCR and culture. Of
the total specimens, 324 (9.5%) yielded a positive
result for M. tuberculosis with at least one of the
media used (Table 1). The mean period for isola-
tion of M. tuberculosis was 14 days in the Bactec
9000MB and 20 days in Lo¨wenstein–Jensen med-
ium. There was a contamination rate with Gram-
positive bacteria of 7.5% among the respiratory
specimens with the Bactec 9000MB. Combined
use of one liquid and one solid medium is
recommended by the CDC for optimum recovery
of mycobacteria [2,4,5].
Nucleic acid amplification assays are often
used for rapid confirmation of suspected tuber-
culosis in patients with specimens positive for
AFB [2,6]. Recent multicentre studies have
shown that the CA-PCR automated system, with
an internal inhibition control, can be used for the
detection of MTB in smear-negative samples
[3,10]. The present study found that nine of 324
samples that yielded MTB in culture, as well as
42 culture-negative specimens, remained inhibi-
tory following dilution and retesting. This pro-
tocol can also elicit false-negative results
following dilution of DNA template in the
samples. Other factors that may affect PCR
reliability have been reported, such as decon-
tamination ⁄fluidification, especially when a high
concentration (4%) of NaOH is used, inefficiency
in the liquefaction procedure, formation of
aggregates by M. tuberculosis, and heterogeneous
repartition of bacilli in specimens [3,11]. Most
specimens that remained inhibited were sputa
(n = 34).
The sensitivity of CA-PCR was higher among
Z-N-positive samples, ranging from 73.6% in
sputa to 100% in non-respiratory body fluids,
while specificity ranged from 80% to 100%,
respectively (Table 1). An overall sensitivity of
86.7% has been reported previously among
smear-positive respiratory specimens, although
expectorated sputa were not distinguished from
BAL specimens [12]. The present study found
that the highest sensitivity of CA-PCR among
samples that were Z-N-negative and culture-
positive for MTB was with sputa collected after
bronchoscopy (70%), followed by sputa (52.1%).
Similarly, Kim et al. [7] reported, without speci-
fying the origin of respiratory specimens, a
sensitivity of 50–75% for CA-PCR among
smear-negative samples. The low number of Z-
N-positive specimens and the relatively low
sensitivity of CA-PCR with BAL samples may
reflect the fact that the low number of bacteria
remaining in these samples is below the detec-
tion limit (650 CFU ⁄ 250 mL for Z-N and
42 CFU ⁄ sample for PCR) [3,10]. A previous
review [13] of 40 studies using commercial and
in-house PCR tests for direct detection of MTB in
pleural fluids reported that the sensitivity of the
Amplicor test ranged from 24% to 52%. How-
ever, since only one PCR- and culture-positive
pleural fluid was identified, no comparison with
the above findings is possible.
The high sensitivity of CA-PCR was demon-
strated by the results of 47 samples from patients
under treatment, of which 42 were AFB- and
culture-negative, but PCR-positive, and five were
AFB-positive (Table 1). Positive PCRs resulting
from the presence of non-viable isolates have
been reported previously [14]. The identification
of 11 samples that were Z-N-positive and PCR-
negative, and which yielded mycobacteria other
than M. tuberculosis by culture, reinforced the
specificity of CA-PCR, even though these speci-
mens were excluded from statistical analysis.
Although the CDC do not recommend CA-PCR
for smear-negative samples [6], this method may
contribute to early detection of MTB, especially
with sputa collected after bronchoscopy.
In conclusion, while sputum samples and BAL
samples are the preferred clinical specimens for
the recovery of MTB, sputa expectorated after
bronchoscopy showed the highest PCR sensitivity
with both Z-N-positive and -negative specimens.
The combination of Z-N staining and CA-PCR
(with an internal control) of sputa collected after
bronchoscopy from a patient with clinical signs of
infection should contribute to the early diagnosis
of tuberculosis.
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